Bris­tol-My­ers of­fers some ea­ger­ly await­ed Check­mate-227 re­sults, but they're not chang­ing med­ical prac­tice -- yet

Ed­i­tor’s note: I asked lung can­cer ex­pert Jack West — a tho­racic on­col­o­gist at the Swedish Can­cer In­sti­tute at Swedish Med­ical Cen­ter — to take a look at the new da­ta from Bris­tol-My­ers Squibb from Check­mate-227. He makes some ex­cel­lent points about the way Bris­tol-My­ers pre­sent­ed this da­ta, with its broad de­f­i­n­i­tion of tu­mor mu­ta­tion bur­den as a bio­mark­er-de­fined end­point. The de­tailed com­ments are worth study­ing close­ly. It’s clear that Bris­tol-My­ers has a sig­nif­i­cant way to go be­fore they can con­vince prac­ti­tion­ers to change the way they treat lung can­cer.
— John Car­roll, Ed­i­tor

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER